Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,067.98 +57.38 (+1.15%) Dow
38,507.34 +267.36 (+0.70%) Nasdaq
15,682.90 +231.59 (+1.50%) Bitcoin USD
66,717.70 +302.17 (+0.45%) CMC Crypto 200
1,435.73 +20.97 (+1.48%)
Karyopharm Therapeutics Inc. (KPTI)
| Previous close | 1.1300 |
| Open | 1.1200 |
| Bid | 1.1000 x 100 |
| Ask | 1.1100 x 100 |
| Day's range | 1.1000 - 1.1700 |
| 52-week range | 0.6170 - 4.0900 |
| Volume | |
| Avg. volume | 1,780,319 |
| Market cap | 128.695M |
| Beta (5Y monthly) | 0.06 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2500 |
| Earnings date | 02 May 2024 - 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.57 |
PR NewswireKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 79,800 restricted stock units (RSUs) to five newly-hired employees. These RSU awards were granted as of March 31, 2024 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Na
- PR Newswire
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and present at the Barclays 26th Annual Global Healthcare Conference in a fireside chat on Wednesday, March 13, 2024 at 9:00 a.m. ET in Miami Beach, FL.
GuruFocus.comInsider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
President and CEO Richard Paulson executed a sale of 99,844 shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI) on March 1, 2024, according to a recent SEC Filing.
